| Views | |
|---|---|
| Pharmacoepidemiologic and clinical rationale for the inclusion of L-arginine and dihydroquercetin in the combined pharmacotherapy of hypertensive patients with COVID-19 | 1 |
| March 2025 | April 2025 | May 2025 | June 2025 | July 2025 | August 2025 | September 2025 | |
|---|---|---|---|---|---|---|---|
| Pharmacoepidemiologic and clinical rationale for the inclusion of L-arginine and dihydroquercetin in the combined pharmacotherapy of hypertensive patients with COVID-19 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
| Views |
|---|
| Views | |
|---|---|
| United Kingdom | 1 |
| Views | |
|---|---|
| Warrington | 1 |